Hawthorne Health and RxE2 Collaborate to Enhance Patient Access in Clinical Trials
Hawthorne Health and RxE2 Partner to Transform Community-Based Clinical Trial Delivery Hawthorne Health, a leader in community-based clinical trial delivery, and RxE2, a pioneer in pharmacist-led clinical trial services, have announced a groundbreaking strategic partnership aimed at revolutionizing the way…
Quanta System Marks 40 Years of Innovation and Unveils Exclusive New Partnership at IMCAS 2025
Quanta System, a leader in medical laser technology, is celebrating a significant milestone in 2025: its 40th anniversary. This momentous occasion not only honors the company’s rich history of technological advancements and breakthroughs but also marks the start of an…
Kyowa Kirin and Swixx BioPharma Expand POTELIGEO® Access for Mycosis Fungoides and Sézary Syndrome in Central and Eastern Europe
Kyowa Kirin and Swixx BioPharma Expand Access to POTELIGEO® for Mycosis Fungoides and Sézary Syndrome in Central and Eastern Europe Kyowa Kirin International (KKI), a fully owned subsidiary of Kyowa Kirin Co. Ltd., in partnership with Swixx BioPharma AG, recently…
Tubulis Doses First Patient in Phase I/IIa Trial of ADC TUB-030 for Advanced Solid Tumors
Tubulis Advances ADC TUB-030 into Clinical Trials for Advanced Solid Tumors Tubulis, a biopharmaceutical company focused on antibody-drug conjugates (ADCs), announced a significant milestone today with the dosing of the first patient in its Phase I/IIa clinical trial, 5-STAR 1-01…
Osta Therapeutics Expands Leadership Team with Two Industry Experts to Combat Antibiotic Resistance
Osta Therapeutics Expands Leadership Team with Two Industry Experts to Combat Antibiotic Resistance Osta Therapeutics Expands Leadership Team to Tackle Antibiotic Resistance Osta Therapeutics, a biotechnology company focused on developing innovative treatments to combat antibiotic resistance, has announced the appointment…
Ethris Announces Positive Phase 1 Results for mRNA Candidate ETH47 in Uncontrolled Asthma
Ethris Announces Promising Phase 1 Clinical Data for mRNA Therapeutic ETH47 in Asthma Treatment Ethris GmbH, a biotechnology pioneer in the development of next-generation RNA therapeutics and vaccines, has announced promising topline results from its completed Phase 1 clinical trial…
Merz Aesthetics Reveals Global Data on the Link Between Self-Confidence, Self-Affirmation, and Aesthetic Treatments
Merz Aesthetics Reveals Global Data on the Link Between Self-Confidence, Self-Affirmation, and Aesthetic Treatments Merz Aesthetics, the world’s largest company in aesthetic medicine, has unveiled the findings of its first global study, “Pillars of Confidence: Global Insights on Aesthetics and…
Owkin Doses First Patient in AI-Optimized Phase I Trial of OKN4395 for Solid Tumors
Owkin, a pioneering AI-biotech company dedicated to transforming drug discovery, development, and diagnostics through agentic AI, has announced the dosing of the first patient in its Phase I clinical trial of OKN4395. The trial commenced on January 22, 2025, and…
Ferrer Recognized for Excellence in Ethical and Responsible Corporate Practices
Ferrer Earns Compliance Leader Verification™ for Exemplary Ethical and Responsible Corporate Practices Ferrer, a globally recognized pharmaceutical company, has been awarded the prestigious Compliance Leader Verification™ by Ethisphere, an organization dedicated to promoting ethical business practices worldwide. This recognition underscores…
Takeda Posts Strong Q3 FY2024 Results, Increases Full-Year Forecast
Takeda (TOKYO:4502/NYSE:TAK) has announced its third-quarter earnings results for fiscal year 2024, reporting significant progress in its Growth & Launch Products. These products experienced robust growth, posting a 14.6% increase at constant exchange rates (CER). The company has upgraded its…
Galderma Leads in Aesthetic Injectables for Weight Loss With New Research & Guidelines
Galderma, a global leader in dermatology, is pioneering research into the effects of medication-driven weight loss on the skin and the importance of incorporating aesthetic treatments into the patient journey. As the prevalence of prescription weight loss medications grows, with…
Virpax Pharmaceuticals, Inc. Prices $6 Million Public Offering of Common Stock and Pre-Funded Warrants
Virpax Pharmaceuticals Announces Public Offering Pricing to Fuel Drug Development and Innovation Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX), a forward-thinking preclinical-stage pharmaceutical company specializing in groundbreaking drug delivery systems for pain management, has unveiled the pricing details of its latest public…